Pre-congress sessions will be day-long courses for those interested in specific topics. There is no additional cost to attend these sessions, but it will be required to reserve a spot to secure a seat. Download full list of pre-congress sessions.
Pre-congress Session I: Fundamentals of PD 
(Simultaneous translation into French)
Pre-congress Session II: Interdisciplinary Care & Parkinson's Disease
Pre-congress Session III: Science & Advocacy
Tuesday, October 1, 2013
Pre-congress Session I : Fundamentals of PD
Target Audience: Non-clinicians, people with Parkinson’s, others
Goal:
Expose
participants to key topics that will be elaborated on in the program. Give them a glimpse of what is to come and
tools to get the most out of the meeting. Introduce the role of PwPs into the
meeting design and success as well as the legacy of the WPC.
Learning
objectives:
- To gain a basic understanding of Parkinson’s,
including the research into the cause(s) of the disease, symptoms, and
therapies;
- To learn the spectrum of care and rehabilitation
options once diagnosed with Parkinson’s;
- To understand future therapies for Parkinson’s.
9:15AM Introduction Tom Isaacs (UK)
9:30AM What is PD? Stanley Fahn (USA)
9:45AM Pathology
of PD Dennis
Dickson (USA)
10:00AM What
causes PD? Marie-Francoise
Chesselet (USA)
10:15AM Q
& A Panel Facilitator: David
Iverson (USA)
10:30AM BREAK
11:00AM Non-motor
features Ronald Pfeiffer (USA)
11:15AM Medical
therapy Christopher
Goetz (USA)
11:30AM Surgical
therapy Andres
Lozano (Canada)
11:45AM Q
& A Panel Facilitator:
David Iverson (USA)
12:00PM LUNCH
1:15PM What you can do after you are diagnosed to stay involved Peter Davison (Canada)
1:30PM Therapeutic options to stay active and involved
- Speech and Parkinson’s Bonnie
Bereskin (Canada)
- Physical therapy and Parkinson’s Terry Ellis (USA)
- Occupational therapy and Parkinson’s Margarita Makoutonina (Australia)
2:15PM Q & A Panel Facilitator: Linda Morgan (USA)
2:30PM BREAK
3:00PM Future therapies
- Stem cells Patrik
Brundin (USA)
- Viral vectors and gene therapy Jeffrey Kordower (USA)
- Drug treatments Olivier
Rascol (France)
3:50PM Q & A Panel Facilitator:
Linda Morgan (USA)
3:55PM Getting the most out of the WPC 2013 Bob Kuhn (Canada)
4:05 PM Wrap-up Bob Kuhn (Canada) & Stanley
Fahn (USA)
Pre-congress Session II : Interdisciplinary Care &
Parkinson’s Disease
Target Audience: Allied health professionals, members of
multidisciplinary teams, health professionals interested in interdisciplinary
care models
Goal: The aim of
this pre-congress course is to provide a forum for discussion of service
delivery models in PD. Current model types will be presented for the purpose of
discussion and will be referenced to a template of current service delivery
components. The ideal model should focus on the complexity of PD, the need to
provide continuity of care and be able to deal with the cumulative morbidities
associated with a chronic illness.
Learning objectives:
- Understand the complexity of PD and its underlying
pathological basis;
- Be aware of the wide variety of factors that need
to be considered in providing comprehensive and continuous care;
- Be able to advise on the development, modification
or redesign of a service model for PD taking into consideration the
organizational infrastructure of the delegate’s institution.
9:00AM Introduction Anne-Louise Lafontaine (Canada)
9:10AM What do we face? Bastiaan
Bloem (Netherlands)
9:40AM How is it addressed? &
Overview
of available delivery options & models currently in use Ruth Hagestuen (USA)
10:10AM What this all means for people with
Parkinson’s Alice Templin (Canada)
10:30AM BREAK
11:00AM Introduction Mark Guttman (Canada)
The role of the Multidisciplinary Team: Evidence that shows
it is working and what UNIQUE contribution these people make to the team.
Panelists
11:20AM General practitioner’s role Christiane Lepage (Canada)
11:40AM Geriatrician’s role Peter Fletcher
(UK)
12:00PM Nurse’s role Lucie
Lachance (Canada)
12:20PM Rehabilitation team’s role Meg Morris (Australia)
12:40PM - 1:10PM Q&A Facilitator: Mark Guttman (Canada)
1:10PM – 2:10PM LUNCH
2:10PM PANEL - Multidisciplinary
teams Introduction: Ruth Hagestuen (USA)
How are these approaches and models different?
What strengths do they offer or weakness do they create?
How do each of these models solve the problem of an individualized approach to care? Or do they?
[20 minute talk + Q&A immediately following each talk]
- 2:15PM Israeli Model - Tel Aviv Nir
Giladi (Israel)
- 2:45PM Netherlands Model – ParkinsonNet Marten
Munneke (Netherlands)
- 3:15PM US Model - Struthers Center Ruth
Hagestuen (USA)
- 3:45PM Australian
Model Meg
Morris (Australia)
- 4:15PM Canadian Model - McGill Movement Disorders Clinic Anne-Louise Lafontaine (Canada)
4:45PM - 5:10PM Q&A from all panelists & audience Bastiaan Bloem, (Netherlands) & Peter Fletcher (UK)
5:10PM - 5:30PM Wrap-up Alice Templin (Canada) & Nir Giladi (Israel)
Pre-congress Session III : Science & Advocacy
Target Audience: These will be crosstalk sessions appropriate for a
mix of the community, including clinicians, researchers, people with
Parkinson’s and others.
Goal:
Expose
participants to unique research being carried out, advocacy programs being run
and others issues related to advancing the understanding of Parkinson’s science
and increasing involvement of people living with Parkinson’s in the process.
Learning
objectives:
- To gain a more elaborate understanding of specific
research being done to advance the understanding of Parkinson’s;
- To learn about the ongoing efforts of community
members to advance advocacy and engage more people with Parkinson’s in the
clinical trial process;
- To understand future therapies for Parkinson’s.
Individual sessions are currently being designed and scheduled. More details to follow.
Sessions to be offered
by:
Michael J. Fox Foundation for Parkinson’s Research
Parkinson’s Disease Foundation
Teva Neuroscience
Medtronic
Print to Page
